[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537072":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":37,"locations":46,"responsibleParty":74,"collaborators":76,"id":83,"slug":25,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":25,"eligibilityCriteria":87,"healthyVolunteers":84,"sex":88,"minAge":89,"maxAge":25,"enrollmentInfo":90,"targetDuration":25,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin hydrochloride extended-release tablets","ACTIVE_COMPARATOR","Metformin hydrochloride extended-release tablets 2000 mg once daily",[13],"Drug: Metformin hydrochloride extended-release tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"Visually identical placebo tablets","PLACEBO_COMPARATOR","Placebo tablet once daily",[19],"Drug: Visually identical placebo Metformin hydrochloride extended-release tablets",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","titrated to 2000 mg once daily",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Visually identical placebo Metformin hydrochloride extended-release tablets","placebo",[15],[31,34],{"name":32,"affiliation":5,"role":33},"Meredith C McCormack, M.D., M.H.S.","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Tianshi D Wu, M.D., M.H.S.","Baylor College of Medicine",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Rachelle Koehl, M.S.","CONTACT","410-955-1530","rkoehl1@jhmi.edu",{"name":32,"role":40,"phone":44,"phoneExt":25,"email":45},"410-550-6205","mmccor16@jhmi.edu",[47,63],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Baltimore","Maryland","21224","United States",{"type":54,"coordinates":55},"Point",[56,57],-76.61219,39.29038,{"lat":57,"lon":56},[60,62],{"name":61,"role":40,"phone":41,"phoneExt":25,"email":42},"Rachelle Koehl",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"facility":36,"status":48,"city":64,"state":65,"zip":66,"country":52,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Houston","Texas","77030",{"type":54,"coordinates":68},[69,70],-95.36327,29.76328,{"lat":70,"lon":69},[73],{"name":35,"role":40,"phone":25,"phoneExt":25,"email":25},{"type":75,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[77,78,81],{"name":36,"class":6},{"name":79,"class":80},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":82,"class":6},"Temple University","100537072",false,"NCT06273072","Metformin IN Asthma for Overweight and Obese Individuals (MINA)","Inclusion Criteria:\n\n* Physician-diagnosed asthma on maintenance therapy\n* Not well-controlled asthma (ACT score \\\u003C20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months)\n* Overweight or obesity: Body mass index ≥25kg\u002Fm2\n* Adult: Age ≥18\n\nExclusion Criteria:\n\n* Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding\n* Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months\n* Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis\n* Active smoking or former smoker with ≥20 pack-year smoking history\n* Chronic kidney disease: estimated glomerular filtration rate ≤60 mL\u002Fmin\u002F1.73 m2\n* Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man\n* Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2x the upper limit of normal or prior diagnosis of liver disease\n* Anemia: hemoglobin \\\u003C 13 g\u002Fdl in males and hemoglobin \\\u003C 11 g\u002Fdl in females\n* Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss\n* Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes)\n* Participation in any other clinical trial (observational studies are permitted)","ALL","18 Years",{"count":91,"type":92},100,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.",[98,99,100],"Asthma","Asthma Chronic","Overweight and Obesity","2026-01-15",{"date":103,"type":104},"2026-01-16","ACTUAL",{"date":106,"type":104},"2024-12-09",{"date":108,"type":92},"2028-12-31",{"name":5,"class":6},2]